Screen Therapeutics Enters Drug Development Partnership
Contact Our Team
For more information about how Halldale can add value to your marketing and promotional campaigns or to discuss event exhibitor and sponsorship opportunities, contact our team to find out more
The Americas -
holly.foster@halldale.com
Rest of World -
jeremy@halldale.com
Screen Therapeutics LLC has formed a partnership with Immunaccel to focus on the discovery and development of next generation cancer immunotherapies.
Screen Therapeutics will combine its immunology expertise,capabilities and know-how with Immunaccel's IP, know-how and proprietary celllines to discover next-generation cancer therapies targeting stromalinteractions in the tumor microenvironment. This transaction is also part of abroader strategy for Immunaccel to leverage its intellectual property (IP) andknow-how in developing human relevant translational platforms.
Underlying the company's programs is a combination ofproprietary ex vivo 3D platforms and well characterized human cell lines thatenable the simulation of the tumor microenvironment. Screen Therapeutics willleverage these platforms to study the tumor stromal barriers that affect T cellactivity and migration of immune cells in tumors.
"With approximately 30-40 percent of patients notresponding to current immunotherapies, it is important to study the stromalfactors that contribute to this phenomenon. Together with advanced imaging andcomplimentary technology platforms, we aim to simulate the various tumor immunemicroenvironments ex vivo, which will allow us to dissect the cross talkbetween immune cells, stromal cells and tumors with the goal of identifyingnovel targets and biomarkers," said Tonya Webb PhD, scientific co-founderon Screen Therapeutics.
